Decoy Therapeutics Inc.
DCOY Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.97
KIRA · Stoqly’s AI analyst, in plain words
- Decoy Therapeutics Inc. lost $12.5M in fiscal 2025.
- Free cash flow was −$5.4M in fiscal 2025, — of revenue.
Market cap
$0.5M
P/E
0.0x
Revenue
—
Net income
−$12.5M
Free cash flow
−$5.4M
Operating margin
—
Decoy Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$12.5M
No. It lost money last year.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What Decoy Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Decoy Therapeutics Inc.
- CIK
- 0001615219
Decoy Therapeutics Inc. · DCOY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.8M | $0.0M | — | — | — |
| Revenue growth | −64.8% | −100.0% | — | — | — |
| Operating margin | −696.3% | — | — | — | — |
| Net income | −$12.8M | −$31.6M | −$12.5M | −$5.6M | −$12.5M |
| Net margin | −693.8% | — | — | — | — |
| Diluted EPS | −$7.72 | −$14.88 | −$30.74 | −$69.54 | −$129.10 |
| Cash | |||||
| Cash from operations | −$10.2M | −$17.6M | −$12.8M | −$4.5M | −$4.8M |
| Capital expenditure | $0.0M | — | — | $0.0M | $0.6M |
| Free cash flow | −$10.2M | — | — | −$4.5M | −$5.4M |
| FCF margin | −554.3% | — | — | — | — |
| Share count change | −89.4% | 28.4% | −80.8% | −80.3% | 20.9% |
| Debt and strength | |||||
| Cash and short-term investments | $29.2M | $12.1M | $5.9M | $2.4M | $10.7M |
| Shareholders' equity | $38.7M | $10.4M | $5.3M | $1.5M | $5.9M |
| Current ratio | — | — | — | 2.0x | 2.1x |
| Returns and quality | |||||
| Return on equity | −41.9% | −128.7% | −160.1% | −164.0% | −338.3% |
| Return on tangible equity | −42.8% | −304.4% | −237.2% | −368.8% | −212.6% |
| Altman Z'' | — | — | — | −96.8 | −30.9 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Decoy Therapeutics Inc. · DCOY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.97 a share, the company is worth $0.5M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001615219). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.